AR103172A1 - Reducción selectiva de residuos de cisteina en anticuerpos il-17 - Google Patents
Reducción selectiva de residuos de cisteina en anticuerpos il-17Info
- Publication number
- AR103172A1 AR103172A1 ARP150104191A ARP150104191A AR103172A1 AR 103172 A1 AR103172 A1 AR 103172A1 AR P150104191 A ARP150104191 A AR P150104191A AR P150104191 A ARP150104191 A AR P150104191A AR 103172 A1 AR103172 A1 AR 103172A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- antigen
- secukinumab
- preparation
- binding fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a métodos para reducir selectivamente CysL97 en una preparación de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos, ej., una preparación de anticuerpos de secukinumab, que ha sido producida de forma recombinante por células de mamífero, También se proporcionan preparaciones purificadas de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos producidos por tales métodos, por ejemplo, preparaciones purificadas de secukinumab, en donde el nivel de anticuerpos IL-17 intactos o fragmentos de unión a antígeno de los mismos (por ejemplo, secukinumab) en la preparación es alto, por ejemplo, al menos aproximadamente 90%, medido por electroforesis capilar de dodecil sulfato de sodio (CE-SDS), y en donde el nivel de actividad de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (por ejemplo, secukinumab) en la preparación es alto, por ejemplo, al menos aproximadamente 92%, medido por cromatografía de intercambio catiónico (CEX).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095361P | 2014-12-22 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103172A1 true AR103172A1 (es) | 2017-04-19 |
Family
ID=55135470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104191A AR103172A1 (es) | 2014-12-22 | 2015-12-18 | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11292833B2 (es) |
| EP (3) | EP4389143A3 (es) |
| JP (4) | JP7021950B2 (es) |
| KR (3) | KR102873279B1 (es) |
| CN (4) | CN114010780B (es) |
| AR (1) | AR103172A1 (es) |
| AU (1) | AU2015370515B2 (es) |
| BR (1) | BR112017010069A2 (es) |
| CA (1) | CA2971541A1 (es) |
| IL (2) | IL251893B2 (es) |
| MX (1) | MX2017008410A (es) |
| PH (1) | PH12017500967A1 (es) |
| RU (2) | RU2719563C2 (es) |
| SG (1) | SG11201703639QA (es) |
| WO (1) | WO2016103146A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903605TA (en) * | 2016-11-07 | 2019-05-30 | Seattle Genetics Inc | Distribution of engineered-cysteine caps |
| FI3661562T3 (fi) | 2017-08-04 | 2024-12-09 | Amgen Inc | Cys-mab:ien konjugointimenetelmä |
| JP2021534151A (ja) * | 2018-08-15 | 2021-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 下流クロマトグラフィーにおける再酸化によるタンパク質断片化制御戦略 |
| CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
| JP7573261B2 (ja) * | 2020-07-28 | 2024-10-25 | 国立大学法人山梨大学 | 抗酸化剤及びその製造方法、医薬組成物及びその製造方法、食品、並びに化粧品 |
| WO2022117773A1 (en) | 2020-12-02 | 2022-06-09 | Fresenius Kabi Deutschland Gmbh | Methods of selectively reducing antibodies |
| EP4267616A1 (en) * | 2020-12-22 | 2023-11-01 | Novartis AG | Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
| WO2024156841A1 (en) * | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| EP4406553A1 (en) * | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| CN118348098B (zh) * | 2024-03-31 | 2025-01-10 | 珠海联邦生物医药有限公司 | 一种用于毛细管电泳检测的凝胶分离缓冲液 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766205A (en) | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| JP3610395B2 (ja) * | 1991-08-26 | 2005-01-12 | 敏一 中村 | 成熟肝実質細胞増殖因子 |
| ES2370235T3 (es) | 2001-02-23 | 2011-12-13 | Immunex Corporation | Recuperación eficaz de proteínas replegadas correctamente. |
| WO2003048357A1 (fr) | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Procede d'activation de proteine |
| AU2003289455A1 (en) | 2002-12-20 | 2004-07-14 | Mitsubishi Pharma Corporation | Method of protecting thiol group of protein |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| SG156672A1 (en) | 2004-10-22 | 2009-11-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| CN101374864A (zh) | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
| RS52459B (sr) | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies Inc. | Stabilizovane kompozicije glukocerebrozidaze |
| HUE037162T2 (hu) | 2007-07-09 | 2018-08-28 | Genentech Inc | Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| PT2437785E (pt) | 2009-06-04 | 2015-04-20 | Novartis Ag | Método de identificação de sítios para conjugação de igg |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| RU2665954C1 (ru) | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| TWI616204B (zh) * | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| JP5782279B2 (ja) | 2011-01-20 | 2015-09-24 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法および基板処理装置 |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| KR20140097178A (ko) | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
| MX371052B (es) * | 2013-02-08 | 2020-01-14 | Novartis Ag | Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios. |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
-
2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/es unknown
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/ja active Active
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/zh active Active
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
- 2015-12-21 KR KR1020237038206A patent/KR102873279B1/ko active Active
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/ko active Active
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 EP EP24170348.7A patent/EP4389143A3/en active Pending
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 EP EP26163760.7A patent/EP4732845A3/en active Pending
- 2015-12-21 BR BR112017010069-0A patent/BR112017010069A2/en not_active Application Discontinuation
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/zh active Active
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/zh active Active
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en not_active Ceased
- 2015-12-21 KR KR1020257034310A patent/KR20250154539A/ko active Pending
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/es unknown
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/zh active Pending
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/ru active
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/ru active
-
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
-
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/ja active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
-
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/ja not_active Withdrawn
-
2024
- 2024-08-12 US US18/800,977 patent/US20250034241A1/en active Pending
- 2024-10-16 JP JP2024181366A patent/JP2025011274A/ja active Pending
-
2025
- 2025-02-27 US US19/065,656 patent/US20260116964A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| CL2019000259A1 (es) | Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584) | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| BR112015027812A2 (pt) | processo contínuo de multietapa para purificação de anticorpos | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| AR087715A1 (es) | Anticuerpos anti pcsk9 y usos de los mismos | |
| AR091218A1 (es) | Agente terapeutico o agente profilactico para los trastornos cognitivos | |
| BR112017003236A2 (pt) | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica | |
| AR096713A1 (es) | Proceso de purificación para anticuerpos monoclonales | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| PE20211214A1 (es) | Variantes de pertuzumab y su evaluacion | |
| CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| CO6351750A2 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5 | |
| EA201391523A1 (ru) | Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток | |
| MX2016009295A (es) | Cromatografia esteril y procesos de fabricacion. | |
| MX389687B (es) | Inmunoglobulinas conjugadas en cys80. | |
| MX2018001686A (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |